Journal
DRUG HEALTHCARE AND PATIENT SAFETY
Volume 11, Issue -, Pages 71-85Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/DHPS.S173050
Keywords
macitentan; pulmonary arterial hypertension; safety; tolerability; efficacy
Categories
Ask authors/readers for more resources
Macitentan is a medication in the endothelin receptor antagonist class, approved for treatment of pulmonary arterial hypertension in 2013 based on the results of the pivotal SERAPHIN Trial (Study with an Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve cliNical outcome). Macitentan was shown in initial trials to reduce the likelihood of a morbidity/mortality event. Real-world use of this medication additionally reveals a reduced risk of hospitalizations related to pulmonary arterial hypertension, improved health-related quality of life scores, potential clinical utility in other conditions (such as chronic thromboembolic pulmonary hypertension and pulmonary hypertension related to congenital heart disease), and has a similar safety profile as demonstrated in initial trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available